Evaluation of the effect of oral enalapril on neutrophil functions: comparison with the in vitro effect of enalapril and enalaprilat.
Polymorphonuclear neutrophils (PMN) participate in the development of myocardial injury by releasing free oxygen radicals and by involvement in the no-reflow phenomenon. Neutrophil-mediated myocardial injury, therefore contributes to the pathogenesis of heart failure. We investigated the effect of oral treatment with enalapril on neutrophil free oxygen radical production, aggregation and adherence in patients with moderate heart failure (New York Heart Association-NYHA II and III degrees). Samples were taken before and 48 h after a single 10 mg oral dose. Oral enalapril inhibited hydrogen peroxide released by unstimulated PMN, but did not affect stimulated H2O2 release, superoxide anion production, adhesion or aggregation of PMN. Enalaprilat in vitro stimulated PMN to release H2O2 and superoxide anions. Furthermore, in the in vitro conditions both enalaprilat and enalapril inhibited hydrogen peroxide release by stimulated cells. We conclude that, despite certain modifications of neutrophil function in vitro, oral administration of enalapril seems to exert a limited biological effect on circulating neutrophils.